Decreased circulating levels of oxytocin in obesity and newly diagnosed type 2 diabetic patients. 2014

Weiyun Qian, and Tianyi Zhu, and Bingqian Tang, and Shuqin Yu, and Hao Hu, and Wenjun Sun, and Ruirong Pan, and Jifang Wang, and Dong Wang, and Ling Yang, and Chaoming Mao, and Libin Zhou, and Guoyue Yuan
Department of Endocrinology (W.Q., T.Z., B.T., S.Y., H.H., W.S., R.P., J.W., D.W., L.Y., C.M., G.Y.), Affiliated Hospital of Jiangsu University, Jiangsu 212001, China; and Ruijin Hospital (L.Z.), Shanghai Institute of Endocrine and Metabolic Diseases, State Key Laboratory of Medical Genomics, Shanghai Jiaotong University Medical School, Shanghai 200025, China.

OBJECTIVE Oxytocin can affect energy homeostasis and has interesting potential as a metabolic disease therapeutic. We detected serum oxytocin levels in obese (OB) and type 2 diabetes mellitus (T2DM) subjects and investigated the relationships between serum oxytocin levels and glycolipid metabolism, insulin resistance, pancreatic β-cell function, and inflammation. METHODS A total of 176 subjects were enrolled in the study, including 88 patients with newly diagnosed T2DM and 88 subjects with normal glucose tolerance (NGT). NGT and T2DM groups were divided into normal-weight (NW) and OB subgroups. We analyzed the concentrations of oxytocin by ELISA. Oral glucose tolerance testing was done, and hemoglobin A1c (HbA1c), blood lipids, and highly sensitive C-reactive protein (hs-CRP) were also measured. Insulin resistance and pancreatic β-cell function were assessed by homeostasis model assessment (HOMA). RESULTS Serum oxytocin levels were lower in the T2DM group than in the NGT group (P < .01). The levels of serum oxytocin in OB subjects were also lower than those in NW subjects (P < .01). Serum oxytocin levels were negatively correlated with body mass index (BMI), waist circumference (WC), waist-to-hip ratio (WHR), HbA1c, fasting plasma glucose (FPG), 2-hour plasma glucose, fasting insulin (FINS), 2-h insulin, total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), HOMA of insulin resistance (HOMA-IR), and hs-CRP and positively correlated with HOMA of β-cell function (HOMA-β) (P < .05). Multiple stepwise regression analysis showed that 2-hour plasma glucose, BMI, and TC were associated with serum oxytocin levels (P < .05). Logistic regression analyses demonstrated that serum oxytocin was significantly associated with T2DM (P < .01). CONCLUSIONS Serum oxytocin levels were decreased in T2DM as well as OB subjects.

UI MeSH Term Description Entries
D007333 Insulin Resistance Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS. Insulin Sensitivity,Resistance, Insulin,Sensitivity, Insulin
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009765 Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
D010121 Oxytocin A nonapeptide hormone released from the neurohypophysis (PITUITARY GLAND, POSTERIOR). It differs from VASOPRESSIN by two amino acids at residues 3 and 8. Oxytocin acts on SMOOTH MUSCLE CELLS, such as causing UTERINE CONTRACTIONS and MILK EJECTION. Ocytocin,Pitocin,Syntocinon
D010186 Pancreatic Function Tests Tests based on the biochemistry and physiology of the exocrine pancreas and involving analysis of blood, duodenal contents, feces, or urine for products of pancreatic secretion. Function Test, Pancreatic,Function Tests, Pancreatic,Pancreatic Function Test,Test, Pancreatic Function,Tests, Pancreatic Function
D002097 C-Reactive Protein A plasma protein that circulates in increased amounts during inflammation and after tissue damage. C-Reactive Protein measured by more sensitive methods often for coronary heart disease risk assessment is referred to as High Sensitivity C-Reactive Protein (hs-CRP). High Sensitivity C-Reactive Protein,hs-CRP,hsCRP,C Reactive Protein,High Sensitivity C Reactive Protein
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D005260 Female Females
D006017 Glycolipids Any compound containing one or more monosaccharide residues bound by a glycosidic linkage to a hydrophobic moiety such as an acylglycerol (see GLYCERIDES), a sphingoid, a ceramide (CERAMIDES) (N-acylsphingoid) or a prenyl phosphate. (From IUPAC's webpage) Glycolipid

Related Publications

Weiyun Qian, and Tianyi Zhu, and Bingqian Tang, and Shuqin Yu, and Hao Hu, and Wenjun Sun, and Ruirong Pan, and Jifang Wang, and Dong Wang, and Ling Yang, and Chaoming Mao, and Libin Zhou, and Guoyue Yuan
March 2017, Diabetes & vascular disease research,
Weiyun Qian, and Tianyi Zhu, and Bingqian Tang, and Shuqin Yu, and Hao Hu, and Wenjun Sun, and Ruirong Pan, and Jifang Wang, and Dong Wang, and Ling Yang, and Chaoming Mao, and Libin Zhou, and Guoyue Yuan
October 2014, Diabetes care,
Weiyun Qian, and Tianyi Zhu, and Bingqian Tang, and Shuqin Yu, and Hao Hu, and Wenjun Sun, and Ruirong Pan, and Jifang Wang, and Dong Wang, and Ling Yang, and Chaoming Mao, and Libin Zhou, and Guoyue Yuan
January 2021, Frontiers in endocrinology,
Weiyun Qian, and Tianyi Zhu, and Bingqian Tang, and Shuqin Yu, and Hao Hu, and Wenjun Sun, and Ruirong Pan, and Jifang Wang, and Dong Wang, and Ling Yang, and Chaoming Mao, and Libin Zhou, and Guoyue Yuan
November 2014, Diabetes research and clinical practice,
Weiyun Qian, and Tianyi Zhu, and Bingqian Tang, and Shuqin Yu, and Hao Hu, and Wenjun Sun, and Ruirong Pan, and Jifang Wang, and Dong Wang, and Ling Yang, and Chaoming Mao, and Libin Zhou, and Guoyue Yuan
December 2022, Archives of physiology and biochemistry,
Weiyun Qian, and Tianyi Zhu, and Bingqian Tang, and Shuqin Yu, and Hao Hu, and Wenjun Sun, and Ruirong Pan, and Jifang Wang, and Dong Wang, and Ling Yang, and Chaoming Mao, and Libin Zhou, and Guoyue Yuan
August 2021, Diabetes research and clinical practice,
Weiyun Qian, and Tianyi Zhu, and Bingqian Tang, and Shuqin Yu, and Hao Hu, and Wenjun Sun, and Ruirong Pan, and Jifang Wang, and Dong Wang, and Ling Yang, and Chaoming Mao, and Libin Zhou, and Guoyue Yuan
January 2018, Diabetes research and clinical practice,
Weiyun Qian, and Tianyi Zhu, and Bingqian Tang, and Shuqin Yu, and Hao Hu, and Wenjun Sun, and Ruirong Pan, and Jifang Wang, and Dong Wang, and Ling Yang, and Chaoming Mao, and Libin Zhou, and Guoyue Yuan
October 2012, International journal of molecular sciences,
Weiyun Qian, and Tianyi Zhu, and Bingqian Tang, and Shuqin Yu, and Hao Hu, and Wenjun Sun, and Ruirong Pan, and Jifang Wang, and Dong Wang, and Ling Yang, and Chaoming Mao, and Libin Zhou, and Guoyue Yuan
June 2022, Iranian journal of immunology : IJI,
Weiyun Qian, and Tianyi Zhu, and Bingqian Tang, and Shuqin Yu, and Hao Hu, and Wenjun Sun, and Ruirong Pan, and Jifang Wang, and Dong Wang, and Ling Yang, and Chaoming Mao, and Libin Zhou, and Guoyue Yuan
January 2020, The American journal of the medical sciences,
Copied contents to your clipboard!